Introduction Etodolac was a popular nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and inflammation. In the United States, it was available in both prescription and over-the-counter forms and was widely prescribed by doctors. Unfortunately, in 2020, the Food and Drug Administration (FDA) announced the recall of Etodolac due to concerns over its safety. In this article, we will explore why this popular pain medication was discontinued and what this means for doctors and patients alike.
Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) that was used to treat mild to moderate pain and inflammation. It was available both as a prescription medication and as an over-the-counter medication. It was widely prescribed by doctors for a variety of conditions including arthritis, menstrual cramps, and other musculoskeletal conditions.
The FDA announced the recall of Etodolac in 2020 due to safety concerns. The FDA noted that the drug had been associated with an increased risk of serious cardiovascular events, including heart attack and stroke. Additionally, the FDA noted that the drug had been associated with an increased risk of gastrointestinal bleeding. As a result, the FDA determined that the risks associated with Etodolac outweighed the benefits and recommended that it be discontinued.
For doctors, the discontinuation of Etodolac means that they can no longer prescribe it to their patients. However, doctors can still prescribe other NSAIDs to treat pain and inflammation. Additionally, doctors should be aware of the potential risks associated with other NSAIDs and should only prescribe them when the benefits outweigh the risks. For patients, the discontinuation of Etodolac means that they may need to find an alternative medication to treat their pain and inflammation. Patients should speak to their doctor about other options that may be available to them. Additionally, patients should be aware of the potential risks associated with other NSAIDs and should only take them if the benefits outweigh the risks.
Etodolac was a popular nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and inflammation. Unfortunately, in 2020, the FDA announced the recall of Etodolac due to safety concerns. This means that doctors can no longer prescribe it to their patients and patients may need to find an alternative medication to treat their pain and inflammation. Doctors and patients should be aware of the potential risks associated with other NSAIDs and should only take them if the benefits outweigh the risks.
1.
Newly identified T-cell subtype may explain treatment-resistant childhood leukemia
2.
Glioblastoma treatment breakthrough shows promise
3.
A computer-aided diagnostic system for improved detection of breast cancer.
4.
Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy
5.
Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.
1.
Liquid Biopsies in Hematology: A Window into the Disease
2.
Unleashing the Power of AI: A Systematic Review of Predictive Biomarker Discovery in Immuno-Oncology
3.
A Visual Guide to Understanding Breast Cancer Staging
4.
Exploring the Latest Treatments for Essential Thrombocythemia
5.
Innovative Marketing Strategies for Oncology Drugs: A Clinician’s Take on Digital and B2B Trends
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
3.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
4.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
5.
Navigating the Complexities of Ph Negative ALL - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation